Rheumnow Podcast
ACR24 - Day3a
Nov 18, 2024
Dr. Philip Mease, a renowned rheumatologist, presents compelling findings on the long-term safety of Bimekizumab for treating axial spondyloarthritis and psoriatic arthritis. Meanwhile, Dr. Eric Dein dives into the nuanced world of rheumatoid arthritis, discussing the critical distinctions between low disease activity and clinical remission. They also explore the implications of statin use alongside JAK inhibitors, shedding light on how these factors affect treatment strategies. Tune in for insights that could reshape RA management!
34:16
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Effective management of rheumatoid arthritis is crucial to reduce the associated risk of osteoporosis and fractures linked to disease activity.
- Sex-based differences in psoriatic arthritis highlight the need for tailored treatment strategies to improve outcomes for both genders.
Deep dives
Impact of Disease Activity on Osteoporotic Fractures in RA Patients
Patients with rheumatoid arthritis (RA) face an elevated risk of osteoporosis and subsequent fractures, particularly influenced by the level of disease activity. Research indicates that higher disease activity results in reduced bone density, leading to increased fracture rates, specifically hip fractures and major osteoporotic fractures. When patients experience high disease activity, they are more susceptible to these fractures compared to those in remission. Addressing this relationship emphasizes the need for effective management of RA to mitigate not only joint symptoms but also the associated risk of osteoporotic fractures.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
